![](https://investorshub.advfn.com/uicon/276021.png?cb=1471598439)
Wednesday, August 31, 2011 12:51:35 PM
VistaGen Therapeutics, Inc., a biotechnology company focused on stem cell-based drug rescue and drug development, recently completed a $3.87 million financing (including cancellation of $1.0 million of debt) to accredited investors, including a $1.5 million investment by Platinum Long Term Growth Fund. The Company is focused on rescuing the investments made by pharmaceutical companies in promising drug candidates that have been “put on the shelf” due to heart toxicity concerns. By combining its stem cell technology platform, Human Clinical Trials in a Test Tube(TM), with modern medicinal chemistry and three-dimensional (3D) “micro-organ” culture systems, the Company plans to create new, safer, proprietary drug rescue variants of once promising original drug candidates.
VistaGen uses its human pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates long before they are ever tested in humans. The Company anticipates that CardioSafe 3D(TM), the first bioassay system derived from its Human Clinical Trials in a Test Tube(TM) platform, will allow it to assess the heart toxicity profile of new drug candidates with greater speed and precision than nonclinical in vitro techniques and other technologies currently used in the drug development process. VistaGen plans to expand its drug rescue capabilities by introducing its second bioassay system, LiverSafe 3D(TM), a human liver cell based toxicity and metabolism bioassay system, next year. The Company’s core goal is to develop a diverse pipeline of new small molecule drug candidates that will be as effective as the original drug candidates discontinued due to safety concerns but without the toxicity that caused them to be put on the shelf.
“Both in our labs in South San Francisco and through our collaboration with Dr. Gordon Keller in Toronto, we have assembled a dedicated and experienced team that is passionate about the transformative potential of our stem cell technology. Our goal is simple: use stem cell technology to make better medicine,” said Shawn K. Singh, Chief Executive Officer, VistaGen in a prior press release.
VistaGen’s technologies were developed over the last 20 years by a prominent Canadian scientist, Dr. Gordon Keller (recently named a “Top 25 Transformational Canadian” for his pioneering stem cell research), and by Dr. Ralph Snodgrass, VistaGen’s founder, President and Chief Scientific Officer. Using mature heart cells produced from pluripotent stem cells, the Company believes its CardioSafe 3D(TM) is capable of predicting the in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in humans.
In parallel with its drug rescue activities, VistaGen also plans to advance numerous pilot preclinical cell therapy programs, including programs focused on autologous bone marrow transplantation, as well as heart, liver and cartilage repair. Each of the programs is based on the proprietary stem cell differentiation and human cell production capabilities of its Human Clinical Trials in a Test Tube(TM) platform.
Additional information about VistaGen can be found at www.vistagen.com
Recent VTGN News
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM